About All-trans-retinol dehydrogenase [NAD(+)] ADH7
All-trans-retinol dehydrogenase [NAD(+)] ADH7 (ADH7) is a protein
from Homo sapiens identified by UniProt accession
P40394, 386 residues long.
MolForge cross-references it against 0 known binders and
71 disease associations.
Target properties
| Protein name | All-trans-retinol dehydrogenase [NAD(+)] ADH7 |
| UniProt accession | P40394 |
| Gene | ADH7 |
| Organism | Homo sapiens |
| Length | 386 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (71)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.40
- upper aerodigestive tract neoplasm · score 0.32
- high altitude adaptation · score 0.26
- glioblastoma multiforme · score 0.16
- alcohol dependence measurement · score 0.15
- cutaneous melanoma · score 0.12
- vitamin D measurement · score 0.10
- alcohol consumption measurement · score 0.10
- triglyceride measurement · score 0.10
- bitter alcoholic beverage consumption measurement · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P40394-F1 | alphafold | PREDICTED | 95.37 | — |
Amino-acid sequence (386 residues)
MFAEIQIQDK DRMGTAGKVI KCKAAVLWEQ KQPFSIEEIE VAPPKTKEVR IKILATGICR TDDHVIKGTM VSKFPVIVGH EATGIVESIG EGVTTVKPGD KVIPLFLPQC RECNACRNPD GNLCIRSDIT GRGVLADGTT RFTCKGKPVH HFMNTSTFTE YTVVDESSVA KIDDAAPPEK VCLIGCGFST GYGAAVKTGK VKPGSTCVVF GLGGVGLSVI MGCKSAGASR IIGIDLNKDK FEKAMAVGAT ECISPKDSTK PISEVLSEMT GNNVGYTFEV IGHLETMIDA LASCHMNYGT SVVVGVPPSA KMLTYDPMLL FTGRTWKGCV FGGLKSRDDV PKLVTEFLAK KFDLDQLITH VLPFKKISEG FELLNSGQSI RTVLTF
Explore All-trans-retinol dehydrogenase [NAD(+)] ADH7 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets